A fast track influenza virus vaccine produced in insect cells

The viral surface protein hemagglutinin (HA) has been recognized as a key antigen in the host response to influenza virus in both natural infection and vaccination because neutralizing antibodies directed against HA can mitigate or prevent infection. The baculovirus-insect cell system can be used for the production of recombinant HA molecules and is suitable for influenza vaccine production where annual adjustment of the vaccine is required. This expression system is generally considered safe with minimal potential for growth of human pathogens. Extensive characterization of this novel cell substrate has been performed, none of which has revealed the presence of adventitious agents. Multiple clinical studies have demonstrated that the vaccine is safe, well-tolerated and immunogenic. The baculovirus-insect cell system could, therefore, be used for the expedited production of a safe and efficacious influenza vaccine. As a result, this technology should provide a fast track worldwide solution for newly emerging influenza strains or pandemic preparedness within a few years.

Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slideHighlights► A recombinant hemagglutinin vaccine (FluBlok) is produced in insect cells. ► Characterization of cell substrate revealed no evidence of adventitious agents. ► The immunogenicity of FluBlok compared favorably to FluZone for Influenza A. ► This technology provides a global solution for fast access to more vaccine.